05 September 2016
Minister for Health Industries Jack Snelling made the appointment noting, “Prof Domdey’s wealth of experience across research, academia and industry makes him the right choice to advise the Government as we continue to grow our life sciences sector, delivering hi-tech, high-value jobs.
“With an extensive track record in industry development, biomedical cluster development and venture capital financing, Prof Domdey’s appointment will strengthen Adelaide’s business ties with European biomedical companies.”
For the last 18 years Prof Domdey has been Managing Director of BioM – a cluster of more than 260 life sciences companies in Munich – which recently signed a business development agreement with Adelaide, helping create links between Adelaide and Munich life sciences companies.
“I’m excited to have the opportunity to bring my experience to Adelaide, and I look forward to working with the Minister, Mr Butcher, Mr Baccanti and the rest of the Health Industries team,” Prof Domdey said.
Prof Domdey is a trained biochemist and has held research positions across Europe and the US and was appointed Professor of Biochemistry at the University of Munich in 1994, the same year he co-founded one of Germany’s first biotech companies, MediGene.
The Health Industries South Australia Advisory Board provides high level strategy and policy advice for developing South Australia's life sciences sector, and is composed of:
Health Industries Chairman Mark Butcher welcomed the appointment on behalf of the Board. “Prof Domdey will complement the expertise we already have on the Health Industries Board and we all look forward to working together, as we continue to help the government develop this important sector of the South Australian economy,” Mr Butcher said.
Health Industries South Australia Chief Executive Marco Baccanti also welcomed the appointment, saying “Prof Domdey’s high standing in the European life sciences community will help Adelaide as we continue to target investment from this important region”.
Prof Domdey’s appointment is for two years, commencing on 1 September 2016.
Forty-three and a half per cent of R&D costs will be reimbursed in cash to eligible companies with an aggregated annual turnover of less than A$20 million. Read more